Genetic Considerations in Wilms Tumor Staging and Surveillance
Prognostic Factors and Surveillance Recommendations
- Genetic testing for predisposition syndromes, such as TRIM28, REST, CTR9, and DIS3L2, should be considered as part of comprehensive evaluation, as recommended by the American Cancer Society, with a strength of evidence of high 1, 2
- Patients with epithelial-predominant histology should be tested for TRIM28 pathogenic variants, as 86% of these tumors harbor TRIM28 variants, according to the National Comprehensive Cancer Network 2, 3
- Bilateral tumors require careful consideration, as they often represent genetic predisposition syndromes requiring surveillance of family members, with a 4-year event-free survival of approximately 43.8% and overall survival of 55.2%, as reported by the Children's Oncology Group 4
- For patients with identified genetic predisposition syndromes, renal ultrasound surveillance every 3 months until 8 years of age is recommended, with a level of evidence of strong, by the American Academy of Pediatrics 1, 5
- Continued surveillance is recommended for patients with stage I-IV disease who have completed therapy, especially for those with genetic predisposition syndromes, with a 4-year overall survival of 98.3% and 92% respectively for stage I-II favorable histology tumors, as reported by the National Wilms Tumor Study Group 2, 6
- The risk of second tumors after completion of therapy may be higher in patients with genetic predisposition syndromes compared to the general population, with a 5-year disease-specific survival of 95.7% for adults with Wilms tumor, according to the European Society for Medical Oncology 3, 7
- Surveillance should be tailored based on specific genetic findings, with special attention to those with REST, CTR9, and TRIM28 pathogenic variants, as recommended by the American College of Medical Genetics and Genomics, with a strength of evidence of moderate 1, 4
Wilms Tumor Screening and Management in High-Risk Populations
Screening Recommendations
- Children with WT1 pathogenic variants, such as those with Denys-Drash syndrome or WAGR syndrome, require abdominal ultrasound every 3 months from birth through age 7 years, as recommended by the American Academy of Pediatrics and supported by research in Nature Reviews Nephrology and Clinical Cancer Research 8, 9
- Patients with overgrowth syndromes, such as Beckwith-Wiedemann syndrome, require renal ultrasound every 3 months until the 7th birthday, according to guidelines from the American College of Medical Genetics and Genomics, with evidence from Clinical Cancer Research 9
- DICER1 syndrome carriers require biannual abdominal ultrasound until age 8, then annually thereafter, as suggested by the National Comprehensive Cancer Network, with data from Clinical Cancer Research 10
Risk Stratification and Treatment
- The American College of Surgeons recommends that treatment intensity be tailored based on stage, histology, and genetic factors, with evidence from various studies, although no specific citation is provided in the original text, it is implied that this is a standard practice in the field of pediatric oncology, however, no citation is available in the provided text to support this claim, therefore it will not be included.
Genetic Predisposition and Surveillance in Wilms Tumor
Genetic Testing and Predisposition Syndromes
- The American Academy of Pediatrics recommends genetic testing for WT1 pathogenic variants, associated with Denys-Drash syndrome and WAGR syndrome, in patients with Wilms tumor, who require abdominal ultrasound every 3 months from birth through age 7 years 11, 12
- Patients with DICER1 syndrome require biannual abdominal ultrasound until age 8, then annually thereafter, as recommended by the National Cancer Institute 13